These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 9698715)

  • 1. Benefits of a clinical pharmacokinetic service in optimising phenytoin use in the western Cape.
    Valodia P; Seymour MA; Kies BM; Folb PI
    S Afr Med J; 1998 Jul; 88(7):873-5. PubMed ID: 9698715
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimization of phenytoin therapy in adults with epilepsy in the Western Cape, South Africa.
    Valodia PN; Seymour MA; Kies BM; Folb PI
    J Clin Pharm Ther; 1999 Oct; 24(5):381-5. PubMed ID: 10583702
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estimation of population pharmacokinetic parameters of free-phenytoin in adult epileptic patients.
    Deleu D; Aarons L; Ahmed IA
    Arch Med Res; 2005; 36(1):49-53. PubMed ID: 15777995
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical outcomes associated with brand-to-generic phenytoin interchange.
    Kinikar SA; Delate T; Menaker-Wiener CM; Bentley WH
    Ann Pharmacother; 2012 May; 46(5):650-8. PubMed ID: 22550275
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Paradoxical seizures in phenytoin toxicity.
    Chua HC; Venketasubramanian N; Tan CB; Tjia H
    Singapore Med J; 1999 Apr; 40(4):276-7. PubMed ID: 10487084
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of over-the-counter cimetidine on phenytoin concentrations in patients with seizures.
    Rafi JA; Frazier LM; Driscoll-Bannister SM; O'Hara KA; Garnett WR; Pugh CB
    Ann Pharmacother; 1999; 33(7-8):769-74. PubMed ID: 10466901
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phenytoin toxicity: an easily missed cause of cerebellar syndrome.
    Brostoff JM; Birns J; McCrea D
    J Clin Pharm Ther; 2008 Apr; 33(2):211-4. PubMed ID: 18315788
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Practical management of therapeutic diphenylhydantoin concentrations in children.
    Smit A; Schoeman JF; Seifart HI; Parkin DP
    S Afr Med J; 1999 Oct; 89(10):1092-7. PubMed ID: 10582067
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adverse effects of carbamazepine, phenytoin, valproate and lamotrigine monotherapy in epileptic adult Chinese patients.
    Zeng K; Wang X; Xi Z; Yan Y
    Clin Neurol Neurosurg; 2010 May; 112(4):291-5. PubMed ID: 20071075
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lower phenytoin serum levels in persons switched from brand to generic phenytoin.
    Sherry JH; Bechtel T
    Neurology; 2005 Aug; 65(4):657-8; author reply 657-8. PubMed ID: 16118859
    [No Abstract]   [Full Text] [Related]  

  • 11. Dilantin jeopardy: avoiding the dangers of phenytoin.
    Schlicher ML
    Medsurg Nurs; 1998 Dec; 7(6):343-7, 356. PubMed ID: 10036438
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lack of a clinically significant effect of zonisamide on phenytoin steady-state pharmacokinetics in patients with epilepsy.
    Levy RH; Ragueneau-Majlessi I; Garnett WR; Schmerler M; Rosenfeld W; Shah J; Pan WJ
    J Clin Pharmacol; 2004 Nov; 44(11):1230-4. PubMed ID: 15496640
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lower phenytoin serum levels in persons switched from brand to generic phenytoin.
    Stetz SA
    Neurology; 2005 Aug; 65(4):657-8; author reply 657-8. PubMed ID: 16118861
    [No Abstract]   [Full Text] [Related]  

  • 14. Lower phenytoin serum levels in persons switched from brand to generic phenytoin.
    Rackley RJ
    Neurology; 2005 Aug; 65(4):657-8; author reply 657-8. PubMed ID: 16118860
    [No Abstract]   [Full Text] [Related]  

  • 15. [Decrease of folic acid and cognitive alterations in patients with epilepsy treated with phenytoin or carbamazepine, pilot study].
    Hernández R; Fernández Mde L; Miranda G; Suástegui R
    Rev Invest Clin; 2005; 57(4):522-31. PubMed ID: 16315636
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum albumin-adjusted phenytoin levels: an approach for predicting drug efficacy in patients with epilepsy, suitable for developing countries.
    Tandon M; Pandhi P; Garg SK; Prabhakar SK
    Int J Clin Pharmacol Ther; 2004 Oct; 42(10):550-5. PubMed ID: 15516024
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The safety, tolerability, and pharmacokinetics of fosphenytoin after intramuscular and intravenous administration in neurosurgery patients.
    Boucher BA; Feler CA; Dean JC; Michie DD; Tipton BK; Smith KR; Kramer RE; Young B; Parks BR; Kugler AR
    Pharmacotherapy; 1996; 16(4):638-45. PubMed ID: 8840370
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validation of population pharmacokinetic parameters of phenytoin using the parallel Michaelis-Menten and first-order elimination model.
    Valodia PN; Seymour MA; McFadyen ML; Miller R; Folb PI
    Ther Drug Monit; 2000 Jun; 22(3):313-9. PubMed ID: 10850399
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic drug monitoring and clinical outcomes in epileptic Egyptian patients: a gene polymorphism perspective study.
    Ebid AH; Ahmed MM; Mohammed SA
    Ther Drug Monit; 2007 Jun; 29(3):305-12. PubMed ID: 17529887
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Concentration-effect relationships with perampanel in patients with pharmacoresistant partial-onset seizures.
    Gidal BE; Ferry J; Majid O; Hussein Z
    Epilepsia; 2013 Aug; 54(8):1490-7. PubMed ID: 23772853
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.